Skip to main content
Premium Trial:

Request an Annual Quote

Cofactor Genomics Awarded $1.5M NIH Grant for Circular RNA Enrichment Tech

NEW YORK (GenomeWeb) – Cofactor Genomics has recently received a $1.5 million Phase II SBIR grant from the National Institutes of Health to further develop a circular RNA enrichment technology.

Circular RNA is noncoding, present in the cytoplasm, plays a role in neuronal development, and can serve as a biomarker for psychiatric disorders, according to Cofactor. In addition, circRNAs are present in lower abundance than other RNA molecules, and share sequence homology with mRNA, so they are difficult to isolate from total RNA.

With a previously awarded Phase I grant, the company said it demonstrated its technology could enrich for circRNAs from multiple sample types. With the latest funding, it plans to optimize the technology, particularly in brain tissue, and develop companion data-analysis software.

Cofactor also plants to use the Phase II grant money to support an ongoing early-access program for a standardized circRNA enrichment kit as it lays the groundwork for commercialization, according to its grant abstract.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.